An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin Containing Regimens
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
GSK Clinical Trials
Study Director
GlaxoSmithKline
United States: Food and Drug Administration
EGF 20002
NCT00051103
October 2002
Name | Location |
---|---|
GSK Investigational Site | Bakersfield, California 93309 |
GSK Investigational Site | Gainesville, Florida 32610 |
GSK Investigational Site | St. Louis, Montana 63110 |
GSK Investigational Site | Raleigh, North Carolina 27609 |
GSK Investigational Site | Fort Worth, Texas 76104 |
GSK Investigational Site | Savannah, Georgia 31405 |
GSK Investigational Site | Park Ridge, Illinois 60068 |
GSK Investigational Site | Bettendorf, Iowa 52722 |
GSK Investigational Site | Baltimore, Maryland 21201 |
GSK Investigational Site | Royal Oak, Michigan 48073 |
GSK Investigational Site | Hooksett, New Hampshire 03106 |
GSK Investigational Site | Fargo, North Dakota 58103 |
GSK Investigational Site | Oklahoma City, Oklahoma 73112 |
GSK Investigational Site | Pittsburgh, Pennsylvania 15213 |
GSK Investigational Site | Columbia, South Carolina 29210 |
GSK Investigational Site | Germantown, Tennessee 38138 |
GSK Investigational Site | Salem, Virginia 24153 |